PALO ALTO, Calif.—Evommune, Inc., a clinical-stage biotechnology firm focused on developing novel therapies for chronic inflammatory diseases, has announced the pricing of its initial public offering (IPO). The company is offering 9,375,000 shares of common stock at a price of $16.00 per share.
The IPO also includes a standard 30-day option for the underwriters to purchase up to an additional 1,406,250 shares at the IPO price, minus underwriting discounts and commissions. The expected gross proceeds from the offering, excluding the potential exercise of the underwriters’ option and deducting underwriting expenses, are projected to be $150 million.
Shares of Evommune are slated to commence trading on the New York Stock Exchange (NYSE) on November 6, 2025, under the ticker symbol “EVMN.” The offering is anticipated to close on November 7, 2025, contingent upon the fulfillment of customary closing conditions.
Morgan Stanley, Leerink Partners, Evercore ISI, and Cantor are serving as the joint book-running managers for the offering. This syndicate brings a wealth of experience in guiding biotech companies through the IPO process, reflecting Evommune’s strategic approach to navigating the public markets.
A registration statement pertaining to these securities has already been filed with the U.S. Securities and Exchange Commission (SEC) and became automatically effective on November 5, 2025. This indicates that Evommune has met all the regulatory requirements necessary to proceed with the offering.
Evommune intends to utilize the proceeds from the IPO to advance its pipeline of drug candidates targeting chronic inflammatory diseases. The company’s approach involves identifying and targeting the key drivers of inflammation, a strategy that could potentially lead to more effective and targeted treatments compared to existing therapies. Industry analysts suggest that this focus on specific inflammatory pathways could give Evommune a competitive edge in a crowded market. The potential impact of Evommune’s IPO on the broader biotech sector is significant. A successful offering could signal increased investor confidence in companies developing innovative therapies for chronic diseases, potentially spurring further investment and development in this area.
About Evommune, Inc.
Evommune, Inc. is dedicated to developing innovative therapies that address the root causes of chronic inflammatory diseases. The company aims to improve the lives of patients and mitigate the long-term consequences of uncontrolled inflammation, which often result from the limitations of current treatment options. Evommune is actively developing a portfolio of differentiated product candidates that target critical drivers of chronic inflammation, signifying a targeted approach to therapeutic intervention.
Forward-Looking Statements
This press release contains forward-looking statements, including those regarding the commencement of trading on the NYSE, the completion and timing of the offering, and the anticipated gross proceeds. These statements are based on Evommune’s current expectations and involve inherent uncertainties, risks, and assumptions that are difficult to predict. Factors that could cause actual results to differ materially include risks and uncertainties related to the satisfaction of closing conditions, completion of the offering, and the inherent risks of biopharmaceutical product development and clinical trials. These and other risks and uncertainties are detailed in the “Risk Factors” section of the final prospectus filed with the SEC. The forward-looking statements are made as of the date of this press release, and Evommune undertakes no obligation to update them except as required by law.
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/12341.html
